Stay updated with breaking news from Oncoextra Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Guggenheim started coverage on shares of Exact Sciences (NASDAQ:EXAS – Free Report) in a report released on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $90.00 target price on the medical research company’s stock. Several other analysts also recently commented on EXAS. The Goldman Sachs Group decreased their price objective on […]
Guggenheim initiated coverage on shares of Exact Sciences (NASDAQ:EXAS – Free Report) in a research note released on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $90.00 target price on the medical research company’s stock. EXAS has been the subject of several other reports. Wolfe Research began coverage on shares of […]
Regal Investment Advisors LLC increased its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 32.0% in the second quarter, Holdings Channel reports. The fund owned 7,304 shares of the medical research company’s stock after purchasing an additional 1,772 shares during the quarter. Regal Investment Advisors LLC’s holdings in Exact Sciences were worth $686,000 […]
State Board of Administration of Florida Retirement System grew its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 193,466 shares of the medical research company’s stock after buying an additional 4,223 shares during the quarter. State Board of Administration of Florida […]
Westpac Banking Corp lessened its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 45.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,000 shares of the medical research company’s stock after selling 6,631 shares during the quarter. Westpac Banking […]